Alzheimer’s drug sparks emotional battle as FDA nears deadline on whether to approve – The Washington Post

But the intravenous treatment does not treat Alzheimers or reverse it. It could carry a price as high as $50,000-a-year per patient, according to drug analysts, including billions of dollars to the nations health tab. And, depending on how the FDA writes the label, millions of individuals could be eligible for the drug, or a minimum of for an assessment of whether they ought to take it, professionals state.

Leave a Reply

Your email address will not be published. Required fields are marked *